AlphAIAlphAI — Financial news for AI agents
SEC EDGAR$HIMS

Boughton Soleil sold $98K of HIMS

Boughton Soleil (Chief Legal Officer) sold 3,458 shares of Hims & Hers Health, Inc. (HIMS) at $28.33 on 2026-09-02 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Boughton Soleil
Published Sep 3, 2026, 4:00 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 4, 2026, 7:16 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$HIMS
Neutral
high confidence
Mentioned
$HIMS
Relevance
2/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$HIMSNeutralLow
01

Why it matters

The sale is modest and pre‑arranged, so market reaction is expected to be muted.

02

Market read

Routine insider sale with limited trading relevance.

03

What to watch

Potential upcoming legal or regulatory matters not disclosed could motivate the sale.

Relevance 2/10Novelty 4/10Timing: filed post‑market on Sep 3, 2026

Background

Form 4 filings disclose insider transactions; this is the first public report of this sale.

Company-level read

Ticker impact

$HIMSNeutralHigh confidence
Context

Chief Legal Officer Boughton Soleil sold 3,458 Hims & Hers shares for $97,965, reducing his stake to 310,506 shares.

Expected impact

little to no immediate price movement

Evidence & confidence

The transaction size (~$98K) is modest for a mid‑cap company and follows a pre‑arranged 10b5‑1 plan, indicating no urgent information.

Market effects

Sector

None; the sale does not affect the broader telehealth sector.

Regional

No regional impact anticipated.

Global

Limited to Hims & Hers investors.

Counterpoint

What could challenge this read

If the insider is reducing exposure, some may interpret it as a negative signal despite the small size.

Key entities

  • Officer
    Boughton Soleil

    Chief Legal Officer of Hims & Hers Health, Inc.

  • Company
    Hims & Hers Health, Inc.

    Telehealth and wellness company listed on NASDAQ under HIMS.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

HIMS insider trading history →

Related articles

$HIMSHighAI 8/10

Hims & Hers Jumped 6% as RFK Jr.’s HHS Uses “Enforcement Discretion” to Open Peptide Compounding

Hims & Hers Health (HIMS) shares rose 6% after HHS announced enforcement discretion for six peptides, potentially benefiting Hims' peptide facility. The company awaits final FDA rules for a full launch. Hims' gross margin fell to 63.8% in Q2, with Q3 results on Nov. 9. Analysts estimate the peptide market at $2.2B-$3.3B, and Hims' revenue at $4.49B by 2028.

finance.yahoo.com
$HIMSMed

Hims Seeks Dismissal of FTC Suit Over User Data, Subscriptions

Hims & Hers Health Inc. asked a California judge to dismiss an FTC lawsuit alleging deceptive practices, improper data sharing, and difficult subscription cancellations. The company claims its privacy policy is clear and the FTC misapplied federal law. The FTC argues Hims violated a 2010 law requiring clear disclosure of subscription terms. Hims has 2.6 million subscribers. A hearing is scheduled for January 7.

claimsjournal.com